Getinge Expects 2026 Organic Net Sales Growth of 3-5%, Adjusted for Surgical Perfusion Phase-Out

Bitget2026/10/21 06:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Getinge expects 2026 organic net sales growth of 3-5%, adjusted for the phase-out of Surgical Perfusion.
Third-quarter organic net sales rose 2.1%, with organic order intake up 2.6%.
The adjusted EBITA margin target is 16-19% by the end of 2028, versus 15.6% on a rolling 12-month basis.
Significant quality cost reductions are expected gradually from the second half of 2026 through 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getinge AB published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Getinge Expects 2026 Organic Net Sales Growth of 3-5%, Adjusted for Surgical Perfusion Phase-Out

You may also like

Crypto prices